Moderna flu vaccine mRNA-1010 faces FDA decision by Aug. 5, 2026 PDUFA date

Moderna

Moderna

MRNA

0.00
  • FDA vaccine advisory panel voted 9-0 that benefits outweigh risks for Moderna’s investigational flu shot mRNA-1010 in adults 50-64, 65+.
  • FDA PDUFA goal date remains Aug. 5, 2026, as the agency reviews the biologics license application.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606181600ACCESSWRNAPR_____1179265) on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.